Bayesian optimization for identification of optimal biological dose combinations in personalized dose-finding trials
Biometrics · 01.07.2026 · 82 (3)
DOI: 10.1093/biomtc/ujag152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biometrics, online erschienen am 10.09.2026. Verfasst von James Willard und 2 weiteren Autor:innen. Beteiligte Einrichtung: MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, United Kingdom. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Precision Medicine, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FRQNT, National Institute for Health Research, NSERC.
Abstract (Originalsprache)
Early-phase, personalized dose-finding trials for combination therapies seek to identify patient-specific optimal biological dose (OBD) combinations, which are defined as safe dose combinations that maximize therapeutic benefit for a specific covariate pattern. Given the small sample sizes that are typical of these trials, it is challenging for traditional parametric approaches to identify OBD combinations across multiple dosing agents and covariate patterns. To address these challenges, we propose a Bayesian optimization approach to dose-finding that incorporates efficacy and toxicity information into the sequential search strategy. Independent Gaussian processes are used to model the efficacy and toxicity surfaces, and an acquisition function is utilized to define the dose-finding strategy. Furthermore, we define an adaptive stopping rule using the posterior entropy for the location of the OBD. This work is motivated by a personalized dose-finding trial which considers a dual-agent therapy for obstructive sleep apnea (OSA), where OBD combinations are tailored to OSA severity. Via a simulation study, the approach is first investigated across varying degrees of response heterogeneity for both efficacy and toxicity, and then a collection of final designs for the OSA trial are compared. We demonstrate that the proposed approach toward personalized dose-finding yields good performance under the considered scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, United Kingdom.
- Department of Epidemiology and Biostatistics, McGill University, Montreal H3A 1Y7, Canada.
ORCID-Profile: James Willard, Shirin Golchi, Erica E M Moodie
Förderung
- FRQNT
- National Institute for Health Research
- NSERC
- FRQS
Zitieren
APA
Willard, J., Golchi, S., & Moodie, E. E. M. (2026). Bayesian optimization for identification of optimal biological dose combinations in personalized dose-finding trials. Biometrics, 82(3). https://doi.org/10.1093/biomtc/ujag152
Vancouver
Willard J, Golchi S, Moodie EEM. Bayesian optimization for identification of optimal biological dose combinations in personalized dose-finding trials. Biometrics. 2026;82(3). doi:10.1093/biomtc/ujag152
BibTeX
@article{Willard2026,
author = {Willard, James and Golchi, Shirin and Moodie, Erica E M},
title = {Bayesian optimization for identification of optimal biological dose combinations in personalized dose-finding trials},
journal = {Biometrics},
year = {2026},
volume = {82},
number = {3},
doi = {10.1093/biomtc/ujag152}
}
EUVIMED